The "CAR T Cell Therapy Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication, Target Antigens, Key Geographical Regions, Key Players and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.
The global CAR T cell therapy market is likely to be worth USD 4.6 billion in 2024, and is projected to reach worth USD 25 billion by 2035, growing at a CAGR of 16.6% during the period 2024-2035.
The new research study consists of industry trends, detailed market analysis, funding and investments analysis, and clinical trial analysis. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the CAR T cell therapy market is poised to grow in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade.
Cancer is one of the leading causes of deaths, globally. In fact, as per World Health Organization (WHO), 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on the affected individuals, their families, communities as well as the national health systems., Presently, there are several conventional approaches, including chemotherapy, radiation therapy and surgery that are used for the treatment of various cancers. However, among the several treatment options that are available to control disease progression and prevent malignant cells from spreading throughout the body, lasting remission is still difficult to achieve.
In order to mitigate the existing challenges related with the conventional treatment approaches, various active initiatives have been undertaken to develop more targeted anti-cancer therapies; of these, CAR T cell therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Immunotherapies essentially make the use of body's own immune system, or its components, to fight against cancer. Over the years, different classes of immunotherapies have emerged as an alternative for the management and treatment of cancer; these include therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors and certain whole cell-based therapies (adoptive cell therapies).
CAR-T cell therapy, which is a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant pharmacological success with targeted antibody-based therapeutics, including monoclonal and conjugated antibodies. Overall, this highly specific and promising form of cell therapy, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Moreover, the ongoing research activity in this field has led to the discovery of several novel molecular targets, further strengthening the research pipeline of the companies in this domain.
Given the consistent increase in number of CAR T cell therapies being developed and launched, the CAR T cell therapy market is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.
Key Companies Involved in CAR T Cell Therapy Market
Examples of key CAR T cell therapy companies include Alaunos Therapeutics, Autolus, Abelzeta Pharma, Bluebird Bio, Bristol Myers Squibb, Carsgen Therapeutics, Cellectis, Gilead Sciences, Innovative Cellular Therapeutics, Kuur Therapeutics, Noile-Immune Biotech, Novartis, Shanghai GeneChem, Sinobioway Cell Therapy, Takara Bio and Wellington Zhaotai Therapies. This global CAR T cell therapy market research report includes an easily searchable excel database of all the companies that are developing CAR T cell therapies.
Recent Developments in the Car T Cell Therapy Market
Several recent developments have taken place in the field of CAR T cell therapy. the analyst has outlined some of these initiatives below. These developments substantiate the overall market trends that have been outlined in the analysis.
- In February 2024, Astellas entered into a strategic agreement with Kelonia with an aim to develop CAR-T cell therapy by combining their iGPS system with later company's ACCEL technology.
- In January 2024, China approved Inaticabtagene Autoleucel, a next generation CD19 targeting CAR-T cell therapy, for the treatment of patients suffering from relapsed or refractory B-cell acute lymphoblastic leukemia.
- In October 2023, the Central Drugs Standard Control Organization approved NexCAR19, a next generation CAR-T cell therapy, for the treatment of patients suffering from advanced lymphoma or leukemia.
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the CAR T cell therapy market, over the forecast period. Based on multiple relevant parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period.
The CAR T cell therapy market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as target indications (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis, Renal Cell Carcinoma and Others), target antigens (CD19, BCMA, CD19 / CD22 and Others), key geographical regions, key players and sales forecast.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 640 |
| Forecast Period | 2024 - 2035 |
| Estimated Market Value (USD) in 2024 | $4.6 Billion |
| Forecasted Market Value (USD) by 2035 | $25 Billion |
| Compound Annual Growth Rate | 16.6% |
| Regions Covered | Global |
CAR T Cell Therapy Market Share Insights
The CAR T cell therapy market report presents an in-depth analysis of various CAR T cell therapy companies in this domain, across different segments, as defined below:
- Historical Trend: 2018-2023
- Base Year: 2023
- Forecast Period: 2024-2035
- Market Size by 2035: $25 Billion
- CAGR: 16.6%
-
Target Indication
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Generalized Myasthenia Gravis
- Hodgkin's Lymphoma
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Ovarian Cancer
- Renal Cell Carcinoma
- Others
-
Target Antigen
- CD19
- BCMA
- CD19 / CD22
- Others
-
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and North Africa
- Rest of the World
-
Key CAR T Cell Therapy Companies Profiled
- Alaunos Therapeutics
- Autolus
- Abelzeta Pharma
- Bluebird Bio
- Bristol Myers Squibb
- Carsgen Therapeutics
- Cellectis
- Gilead Sciences
- Innovative Cellular Therapeutics
- Kuur Therapeutics
- Noile-Immune Biotech
- Novartis
- Shanghai GeneChem
- Sinobioway Cell Therapy
- Takara Bio
- Wellington Zhaotai Therapies
- PowerPoint Presentation
-
Excel Data Packs
- Market Landscape
- Clinical Trial Analysis
- Funding and Investments Analysis
- Partnerships and Collaborations
- Patent Analysis
- Market Forecast and Opportunity Analysis
For more information about this report visit https://www.researchandmarkets.com/r/e8xor4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610989082/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
